U.S. markets close in 1 hour 49 minutes

SAB Biotherapeutics, Inc. (SABS)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.7900-0.0505 (-6.01%)
As of 01:56PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close0.8405
Bid0.7900 x 900
Ask0.8100 x 900
Day's Range0.7828 - 0.8500
52 Week Range0.3660 - 1.4500
Avg. Volume62,404
Market Cap41.332M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.5600
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SABS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SAB Biotherapeutics, Inc.
    Daily – Vickers Top Insider Picks for 02/22/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • Exec Edge

    SAB Biotherapeutics Starts Human Clinical Trial of Diabetes Treatment

    By Healthcare Edge Editorial Staff SAB Biotherapeutics, Inc. (Nasdaq: SABS), which is trying to slow down the progression of type 1 diabetes, said it started trials of SAB-142 on humans in Australia. SAB-142 is the first fully-human anti-thymocyte immunoglobulin treatment and this trial is the first-in-man clinical study, the company said. The program […]

  • GlobeNewswire

    SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

    First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG) SAB-142 directly and specifically targets multiple immune cells involved in the destruction of insulin-producing pancreatic beta cells to potentially preserve beta cell function SAB Biotherapeutics is pursuing IND and CTA filings with U.S. FDA and EMA in 2024 to clinically advance development of SAB-142 into Phase 2b study SIOUX FALLS, S.D., Nov. 29, 2023

  • GlobeNewswire

    SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

    SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Katie Ellias has been appointed to the Company’s Board of Directors. With Ms. Ellias’ appointment, the SAB Biotherapeutics Board is composed of ten directors, eight of whom are